US FDA Greenlights iPLEDGE Changes

The US Food and Drug Administration (FDA) approved changes to the iPLEDGE REMS Program, designed to reduce administrative burdens while maintaining safety for acne patients taking isotretinoin-containing drugs.

The modifications should go into effect by mid-August 2026.

Patients on isotretinoin-containing drugs may now complete required pregnancy testing at home or in other non-medical settings, the FDA stated. Pre-treatment tests must be done in a medical setting, and prescribers must establish processes and procedures to minimize the risk of misinterpretation and falsification of at-home test results.

The 19-day lockout requirement has also been removed from the iPLEDGE REMS Program. If a patient who can get pregnant did obtain their prescription within the seven-day window, a repeat pregnancy test can be done immediately without an additional waiting period, the FDA states. If the patient has not received their first dose of isotretinoin, the test must be done in a medical setting.

In addition, monthly counseling documentation is now removed. Patients who can’t get pregnant must be counseled at enrollment,  but monthly counseling documentation is no longer required.

Until the changes go into effect, the FDA will exercise enforcement discretion regarding pregnancy testing requirements, allowing prescribers to use pregnancy tests that are not performed in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories and permit patients to complete and report home pregnancy tests during and after isotretinoin treatment, if procedures are established to ensure accurate documentation of at-home pregnancy test results.

Acne Experts React

“It’s great to see that changes will finally be made to this onerous system to make a curative medication more available to our patients afflicted by acne,” says Emmy Graber, MD, MBA, President of The Dermatology Institute of Boston in Boston, MA, and Founder and Director, ARM Yourself With Knowledge Virtual Meeting Series. “Removing the 19-day lockout will be especially helpful for patients eager to start their medication.”